An interventional study of Tablet-based Physical SuperBrain BOOM and Smartphone-based SuperBrain BOOM in Mild Cognitive Impairment (MCI), sponsored by Ajou University School of Medicine. Completed at 4 sites in South Korea. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Ajou University School of Medicine · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of — 17 open to participants now, 24 under way, 5 of them phase 3. Cognitive Dysfunction · Korea, Republic of.
Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, this one is the 40th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2026, is one of 37 with no phase, and was the 65th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →17 of the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, United States, Japan and 1 more country
Ages 55–85
Deepsonbio · Sites in Korea, Republic of
Ages 55–90
NeuroBiogen Co., Ltd · Sites in Korea, Republic of
Ages 50–85
Bristol-Myers Squibb · Sites in Korea, Republic of, United States, Argentina and 16 more countries
Ages 60–85
Hoffmann-La Roche · Sites in Korea, Republic of, United States, Argentina and 12 more countries
Ages 50–90
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 94 across the 57 interventional studies, 163 across the 17 observational. Of the 34 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 74 have an industry lead sponsor. The 10 most frequent:
Ajou University School of Medicine is the lead sponsor of 173 studies on the registry; 16 are open to participants now.
Ajou University School of Medicine has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
10 of the studies in Cognitive Dysfunction with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07239310DeepsonbioNeuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease | 2026-12 |
| NCT07334366Pusan National University Yangsan HospitalBroccoli Sprout Extract for Cognitive Function | 2026-12-30 |
| NCT07011680Pusan National University Yangsan HospitalPhospholipid-rich Dairy Extract for Cognitive Function | 2026-12-30 |
| NCT06786676Amyloid Solution IncA Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether a mobile-based personalized physical activity program called SuperBrain BOOM is safe and works to improve cognitive function, physical performance, mood, and quality of life in older adults (ages 50-85) with mild cognitive impairment (MCI).
The main questions it aims to answer are:
Can SuperBrain BOOM be safely and effectively used by people with MCI? Does the program help improve cognitive and physical function? Do participants stay engaged and complete the program as expected?
Researchers will compare:
A mobile intervention group using SuperBrain BOOM (on tablet or smartphone) A control group receiving usual care
Participants will:
Use a tablet or smartphone to follow a personalized physical activity program for 12 weeks Complete clinical assessments on cognition, physical ability, mood, and nutrition Be monitored for safety and program adherence using automatically collected data
This study is designed to assess the feasibility, safety, and potential benefits of a multi-domain personalized physical activity intervention-SuperBrain BOOM-delivered via mobile devices (tablet or smartphone) for individuals with Mild Cognitive Impairment (MCI).
Mild Cognitive Impairment is a condition in which individuals experience noticeable cognitive decline without significant impairment in daily functioning. It is considered a transitional stage between normal aging and dementia. Evidence suggests that regular physical activity and cognitive engagement can delay or reduce the risk of progression to dementia.
SuperBrain BOOM provides personalized exercise programs tailored to each participant's cognitive status, physical capacity, and lifestyle, and is designed to improve cognitive function, physical performance, emotional well-being, and quality of life.
This randomized controlled trial will allocate participants into three groups: a mobile intervention group (tablet or smartphone) and a control group receiving usual care. The primary outcomes include changes in cognitive function, physical performance, mood, nutritional status, and quality of life over 12 weeks. Safety and adherence will be monitored throughout the intervention using system-generated data and clinical assessments.
Secondary analyses will explore subgroup differences based on APOE genotype and demographic variables to better understand who benefits most from the intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meets all of the core clinical criteria for suspected Mild Cognitive Impairment (MCI) according to the National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines as of the screening date:
Has one or more of the following neuropsychological test results within one year of the screening date, with delayed recall scores in the memory domain below the mean -1.0 standard deviation according to age- and education-adjusted normative data:
Has a caregiver who regularly contacts the participant:
-A caregiver who is able to support the participant (monitor compliance and report participant status) and spends at least 8 hours per week with the participant during the trial period.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Tablet-based Physical SuperBrain BOOM
Device: Smartphone-based SuperBrain BOOM
This intervention is a tablet-based physical activity program designed for patients with Mild Cognitive Impairment (MCI). Participants receive a personalized exercise plan through a tablet application, with real-time feedback to enhance cognitive function. Compared to the smartphone-based version, this program is designed to provide a larger interface and structured environment, allowing participants to engage in the program using a tablet at home or in a clinical setting. The app also helps track progress and encourage adherence to the exercise regimen.
This intervention is a smartphone-based physical activity program designed for MCI patients. Participants receive a personalized exercise plan through a smartphone app, with real-time feedback to enhance cognitive function. Unlike the tablet-based intervention, this program is designed to be more portable and flexible, enabling participants to engage in the program from anywhere using their smartphones. The app also helps track progress and encourage adherence to the exercise regimen.
14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14)
The ADAS-cog14 is a comprehensive cognitive assessment tool that includes memory, attention and concentration, planning and executive function, visuoconstruction, and orientation. Scores range from 0 to 90, with higher scores indicating worse cognitive function. The assessment will be conducted at baseline and at the end of the intervention (Week 12).
Time frame: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
Korean Mini-Mental State Examination, 2nd Edition (K-MMSE-2)
The Korean Mini-Mental State Examination, 2nd Edition (K-MMSE-2), is a brief cognitive screening tool widely used to assess general cognitive function. It evaluates orientation, memory, attention and calculation, visuospatial ability, and language through verbal and written tasks. Scores range from 0 to 30, with higher scores indicating better cognitive function. The assessment will be conducted at screening and at the end of the intervention (Week 12).
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Clinical Dementia Rating scale - Sum of Boxes (CDR-SB)
The Clinical Dementia Rating scale - Sum of Boxes (CDR-SB) is used to assess the overall severity of dementia across six domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The total score ranges from 0 to 18, with higher scores indicating more severe cognitive impairment. The assessment will be conducted at screening and at the end of the intervention (Week 12).
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Korean Instrumental Activities of Daily Living (K-IADL)
The Korean Instrumental Activities of Daily Living (K-IADL) is an 11-item assessment tool used to evaluate functional independence in daily life activities, including telephone use, shopping, food preparation, housekeeping, and medication management. Each item is scored from 0 to 3, and a mean score of 0.4 or higher suggests possible dementia. Higher scores indicate greater impairment in instrumental activities of daily living. The assessment will be conducted at screening and at the end of the intervention (Week 12).
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Timed Up and Go test
The Timed Up and Go (TUG) test is used to assess mobility and balance. Participants are seated on a chair placed 3 meters from a cone, with both feet on the ground and hands on their thighs. At the signal to start, they rise from the chair, walk to the cone, circle it, return, and sit down. After a demonstration and one practice trial, the test is performed twice, and the better of the two times (in 0.1-second units) is recorded. The assessment will be conducted at baseline and at the end of the intervention (Week 12).
Time frame: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
30-second Sit-to-Stand Test
The 30-second sit-to-stand test is used to assess lower body strength and endurance. Participants sit in a chair with arms crossed over the chest and hands resting on the shoulders. They are instructed to fully stand up and sit down as many times as possible within 30 seconds, keeping the knees, hips, and back extended. The number of repetitions is automatically recorded by the app. The test will be conducted at baseline and at the end of the intervention (Week 12).
Time frame: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
2-Minute Step Test
The 2-Minute Step Test is used to assess aerobic endurance. Participants are instructed to march in place for 2 minutes, lifting their knees to a height midway between the patella (kneecap) and iliac crest (hip). Each time the right knee reaches the required height, one count is recorded. The final score is calculated by dividing the total step count by 2. The test will be conducted at baseline and at the end of the intervention (Week 12).
Time frame: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
Quality of Life-Alzheimer's Disease (QOL-AD)
The Quality of Life-Alzheimer's Disease (QOL-AD) scale is a 13-item questionnaire designed to assess the quality of life in individuals with Alzheimer's disease. It includes both self-report from the participant and proxy-report from a caregiver. Total scores range from 0 to 52, with higher scores indicating better perceived quality of life. The assessment will be conducted at screening and at the end of the intervention (Week 12).
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Nutritional Quotient for Elderly (NQ-E)
The Nutritional Quotient for Elderly (NQ-E) is a 20-item self-administered questionnaire developed to comprehensively assess dietary quality and nutritional status in older adults. Participants are asked to read and respond to items related to dietary behaviors, balance, diversity, moderation, and dietary environment. The total score ranges from 0 to 100, with higher scores indicating better nutritional status and quality of diet. The assessment will be conducted at baseline and at the end of the intervention (Week 12).
Time frame: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
Mini Nutritional Assessment (MNA)
The Mini Nutritional Assessment (MNA) is a validated screening tool for evaluating nutritional status in older adults. It includes questions on recent food intake, weight loss, mobility, psychological stress, and body mass index (BMI). The total score ranges from 0 to 14, with higher scores indicating better nutritional status. The assessment will be conducted at baseline and at the end of the intervention (Week 12).
Time frame: Baseline (Week 0, pre-intervention) and Week 12 (end of intervention)
Assessment of Metabolic and Vascular Risk Factors
This assessment includes vital signs and anthropometric measurements (blood pressure, waist circumference, weight, body mass index), as well as lifestyle factors (alcohol consumption and smoking status). Additionally, blood tests will be conducted to evaluate metabolic and vascular risk markers, including fasting glucose, HbA1c, total cholesterol, triglycerides, HDL-C, LDL-C, BUN, and creatinine. Blood samples (8 cc) will be collected at screening and at the end of the intervention and analyzed by Seoul Clinical Laboratories. Higher levels of glucose, lipids, or renal markers may indicate elevated cardiometabolic risk.
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Geriatric Depression Scale-15 items (GDS-15)
The Geriatric Depression Scale-15 items (GDS-15) is a self-report screening tool designed to assess depressive symptoms in older adults. Participants respond "yes" or "no" to 15 questions related to mood, energy, and interest. Total scores range from 0 to 15, with higher scores indicating greater severity of depressive symptoms. In the Korean validation study, a score of 8 or higher suggests the possibility of depression. The assessment will be conducted at screening and at the end of the intervention (Week 12).
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Prospective and Retrospective Memory Questionnaire (PRMQ)
The Prospective and Retrospective Memory Questionnaire (PRMQ) is a 16-item self- and proxy-report questionnaire that assesses everyday memory performance. Each item is rated on a 5-point scale (1 to 5), with total scores ranging from 16 to 80. Lower scores indicate better memory function, while higher scores suggest more frequent memory failures. Both the participant and a caregiver will complete the questionnaire at screening and at the end of the intervention (Week 12).
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is a 7-component self-report questionnaire used to assess subjective sleep quality over the past month. It evaluates sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each component is scored from 0 to 3, and the total score ranges from 0 to 21. A total score of 8 or less indicates good sleep quality, while a score of 9 or higher suggests poor sleep quality. The assessment will be conducted at screening and at the end of the intervention (Week 12).
Time frame: Screening (within 14 days prior to baseline) and Week 12 (end of intervention)
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Sep 2026, 6 months.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 6 months is below that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Sep 2026, on Oct 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ajou University School of Medicine →